Fluorothalidomide: A characterization of maternal and developmental toxicity in rabbits and mice

Toxicological Sciences

Volumn 122, Issue 1, 2011, Pages 157-169

  Lee, Crystal J J ^a   Shibata, Norio ^b   Wiley, Michael J ^c   Wells, Peter G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Embryopathies; Fluorinated analog; Hydrolysis; Teratogenesis; Thalidomide

Indexed keywords

FLUOROTHALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; EMBRYO; EMBRYO CULTURE; EMBRYO DEVELOPMENT; EMBRYOPATHY; ENVIRONMENTAL EXPOSURE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOMER; LIMB BUD; MALE; MOUSE; NONHUMAN; PRENATAL EXPOSURE; RABBIT; STEREOCHEMISTRY; TERATOGENESIS; TERATOGENICITY;

MUS; ORYCTOLAGUS CUNICULUS;

EID: 79960156429     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr086     Document Type: Article

References (38)

1. Amin, R. P., Fuchs, A., Christian, M. S., Latriano, L., Weinbauer, G. F., Bryan, P., Laskin, O. L., and Hui, J. Y. (2009). An embryo-fetal developmental toxicity study of lenalidomide in Cynomolgus monkeys. Birth Defects Res. A(Abstract No. P39).
2. Blaschke, G., Kraft, H. P., Fickentscher, K., and Kohler, F. (1979). Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers. Arzneimittelforschung 29, 1640-1642.
3. Carney, E. W., Tornesi, B., Keller, C., Findlay, H. A., Nowland, W. S., Marshall, V. A., and Ozolins, T. R. (2007). Refinement of a morphological scoring system for postimplantation rabbit conceptuses. Birth Defects Res. B 80, 213-222.
4. Castilla, E. E., Ashton-Prolla, P., Barreda-Mejia, E., Brunoni, D., Cavalcanti, D. P., Correa-Neto, J., Delgadillo, J. L., Dutra, M. G., Felix, T., Giraldo, A., et al. (1996). Thalidomide, a current teratogen in South America. Teratology 54, 273-277.
5. Chung, F., Palmer, B. D., Muller, G. W., Man, H.W., Kestell, P., Baguley, B. C., and Ching, L. M. (2003). Effects of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncol. Res. 14, 75-92.
6. Eriksson, T., Bjorkman, S., Roth, B., Fyge, A., and Hoglund, P. (1995). Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7, 44-52.
7. Eriksson, T., Bjorkman, S., Roth, B., and Hoglund, P. (2000). Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J. Pharm. Pharmacol. 52, 807-817.
8. Fabro, S., Smith, R. L., and Williams, R. T. (1967a). The fate of [14C]thalidomide in the pregnant rabbit. Biochem. J. 104, 565-569.
9. Fabro, S., Smith, R. L., and Williams, R. T. (1967b). Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215, 296.
10. Franks, M. E., Macpherson, G. R., and Figg, W. D. (2004). Thalidomide. Lancet 363, 1802-1811.
11. Heger, W., Klug, S., Schmahl, H. J., Nau, H., Merker, H. J., and Neubert, D. (1988). Embryotoxic effects of thalidomide derivatives on the non-human primate Callithrix jacchus; 3. Teratogenic potency of the EM 12 enantiomers. Arch. Toxicol. 62, 205-208.
12. Hoglund, P., Eriksson, T., and Bjorkman, S. (1998). A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J. Pharmacokinet. Biopharm. 26, 363-383.
13. Lee, C. J. J., Goncxalves, L. L., and Wells, P. G. (2011a). Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)-dependent, reactive oxygen species (ROS)-mediated mechanism. FASEB J. Accessed April 18, 2011. doi:10.1096/fj.10-178814 fj.10-178814.
14. Lee, C. J. J., Goncxalves, L. L., and Wells, P. G. (2011b). Resistance of CD-1 and ogg1 DNA repair-deficient mice to thalidomide and hydrolysis product embryopathies in culture. Toxicol. Sci Accessed April 19, 2011. doi:10.1093/toxsci/KFR084.
15. Lenz, W. (1988). A short history of thalidomide embryopathy. Teratology 38, 203-215.
16. Man, H. W., Corral, L. G., Stirling, D. I., and Muller, G. W. (2003). a-Fluorosubstituted thalidomide analogues. Bioorg. Med. Chem. Lett. 13, 3415-3417.
17. Melchert, M., and List, A. (2007). The thalidomide saga. Int. J. Biochem. Cell Biol. 39, 1489-1499.
18. Merker, H. J., Heger, W., Sames, K., Sturje, H., and Neubert, D. (1988). Embryotoxic effects of thalidomide-derivatives in the non-human primate Callithrix jacchus. I. Effects of 3-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-dioxopiperidine (EM12) on skeletal development. Arch. Toxicol. 61, 165-179.
19. Miyachi, H., Azuma, A., Hioki, E., Iwasaki, S., Kobayashi, Y., and Hashimoto, Y. (1996). Cell-type/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence. Biochem. Biophsy. Res. Commun. 224, 426-430.
20. Miyachi, H., Kioso, Y., Shirai, R., Niwayama, S., Liu, J. O., and Hashimoto, Y. (1998). Tumor necrosis factor-alpha production enhancing activity of substituted 3'-methylthalidomide: influence of substituents at the phthaloyl moiety on the activity and stereoselectivity. Chem. Pharm. Bull. 46, 1165-1168.
21. Ng, S. S., Gutschow, M., Weiss, M., Hauschildt, S., Teubert, U., Hecker, T. K., Luzzio, F. A., Kruger, E. A., Eger, K., and Figg, W. D. (2003). Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res. 63, 3189-3194.
22. Nishimura, K., Hashimoto, Y., and Iwasaki, S. (1994). (S)-form of alphamethyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production in human leukemia cell HL-60: implication of optical resolution of thalidomide effects. Chem. Pharm. Bull. 42, 1157-1159.
23. Niwayama, S., Loh, C., Turk, B. E., Liu, J. O., Miyachi, H., and Hashimoto, Y. (1998). Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action. Bioorg. Med. Chem. Lett. 8, 1071-1076.
24. Park, B. K., Kitteringham, N. R., and O'Neill, P. M. (2001). Metabolism of fluorine-containing drugs. Annu. Rev. Pharmacol. Toxicol. 41, 443-470.
25. Parman, T., Wiley, M. J., and Wells, P. G. (1999). Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 5, 582-585.
26. Pitt, J. A., and Carney, E. W. (1999a). Development of a morphologicallybased scoring system for postimplantation New Zealand White rabbit embryos. Teratology 59, 88-101.
27. Pitt, J. A., and Carney, E. W. (1999b). Evaluation of various toxicants in rabbit whole embryo culture using a new morphologically-based evaluation system. Teratology 59, 102-109.
28. Schuler-Faccini, L., Soares, R. C. F., de Sousa, A. C. M., Maximino, C., Luna, E., Schwartz, I. V. D., Waldman, C., and Castilla, E. E. (2007). New cases of thalidomide embryopathy in Brazil. Birth Defects Res. A 79, 671-672.
29. Schumacher, H., Blake, D. A., Gurian, J. M., and Gillette, J. R. (1968). A comparison of the teratogenic activity of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 160, 189-200.
30. Smith, S. W. (2009). Chiral toxicology: it's the same thing... only different. Toxicol. Sci. 110, 4-30.
31. Somers, G. F. (1962). Thalidomide and congenital abnormalities. Lancet 279, 912-913.
32. Takeuchi, Y., Tomoki, S., Kenichi, K., Suzuki, E., and Shibata, N. (1999). (R)- and (S)-3-fluorothalidomides: isosteric analogues of thalidomide. Org. Lett. 1, 1571-1573.
33. Teo, S. K., Chen, Y.,Muller, G. W., Chen, R. S., Thomas, S. D., Stirling, D. I., and Chandula, R. S. (2003). Chiral inversion of the second generation IMiD CC-4047 (ACTIMID) in human plasma and phosphate-buffered saline. Chirality 15, 348-351.
34. Therapontos, C., Erskine, L., Gardner, E. R., Figg, W. D., and Vargesson, N. (2009). Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc. Natl. Acad. Sci. U.S.A. 106, 8573-8578.
35. Webster, S. W., Brown-Woodman, P. C. D., and Ritchie, H. E. (1997). A review of the contribution of whole embryo culture to the determination of hazard and risk in teratogenicity testing. Int. J. Dev. Biol. 41, 329-335.
36. Williams, R. T. (1968). Thalidomide. A study of biochemical teratology. Arch. Environ. Health 16, 493-502.
37. Winn, L. M., and Wells, P. G. (2002). Evidence for Ras-dependent signal transduction in phenytoin teratogenicity. Toxicol. Appl. Pharm. 184, 144-152.
38. Wnendt, S., Finkam, M., Winter, W., Ossig, J., Raabe, G., and Zwingenberger, K. (1996). Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues. Chirality 8, 390-396.